Skip to main content
. 2000 Oct 17;97(22):12204–12209. doi: 10.1073/pnas.200348397

Table 1.

Diabetogenic effect of anti-CTLA-4 mAb treatment in the naive BDC2.5 T cell transfer system

Treatment Insulitis at d7 Diabetes
Ctl mAb Mild, nonaggressive 3 /18
α-CTLA-4 mAb Aggressive 7 /8

Adult Cαo/o/NOD hosts received 1–2 × 107 erythrocyte-depleted splenocytes from 10- to 12-day-old BDC2.5/NOD donors. The indicated mAbs were routinely given at the time of transfer and 3 days later.